Back to top
more

Twist Bioscience (TWST)

(Delayed Data from NSDQ)

$41.57 USD

41.57
657,566

+1.21 (3.00%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $41.22 -0.35 (-0.84%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 32.11% and 0.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Upgraded to Buy: What Does It Mean for the Stock?

Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 28.91% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 35.82% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Surges 16.1%: Is This an Indication of Further Gains?

Twist Bioscience (TWST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of -2.08% and 92.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 9.33% and 18.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Twist Bioscience (TWST) Upgraded to Buy: What Does It Mean for the Stock?

Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 16.92% and 9.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Twist Bioscience (TWST) Stock Jumps 7.7%: Will It Continue to Soar?

Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 1.59% and 5.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Twist Bioscience (TWST) Q2 Earnings Expected to Decline

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 15.74% and 10.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Twist Bioscience (TWST) Q1 Earnings Expected to Decline

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Nov 23, 2021

Companies In The News Are: TSLA, AVYA, ZH, TWST.

Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of -5% and 3.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Twist Bioscience (TWST) Q4 Earnings Expected to Decline

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of -7.89% and 7.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?

Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of -2.63% and 12.56%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?